Human Vaccines & Immunotherapeutics (Oct 2021)

Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management

  • Oriana Simonetti,
  • Giulia Radi,
  • Elisa Molinelli,
  • Giulio Rizzetto,
  • Federico Diotallevi,
  • Annamaria Offidani

DOI
https://doi.org/10.1080/21645515.2021.1925502
Journal volume & issue
Vol. 17, no. 10
pp. 3268 – 3275

Abstract

Read online

Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects approximately 20% of children and 10% of adults. The implication of vaccines as a trigger for the de novo onset of AD in children or as a cause of exacerbation in individuals with a history of AD has long been debated. We present a brief review of the literature on AD and traditional vaccinations, proposing in addition the main recommendations for the management of patients with AD undergoing the vaccine against the SARS-COV-2 virus. Live attenuated vaccines seem to be associated with a relapse of AD and/or complications, such as eczema vaccinatum. For non-live vaccines, no adverse events are noted in atopic subjects. Since the Covid-19 vaccine is mRNA or viral vectored vaccine and there are no other currently used vaccines of this type, the same recommendations are applied as for all other non-live vaccines.

Keywords